Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novartis AG
Improving gender balance in top pharma is a slow process, but not a gradual one. Management shake-ups often implemented by newly appointed CEOs could help.
The anti-CD20 monoclonal antibody Arzerra (ofatumumab) has not been recommended for the maintenance therapy of relapsed chronic lymphocytic leukemia (CLL), an expanded indication, by the Committee for Medicinal Products for Human Use (CHMP).
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.